Heidelberg Spectralis OCT

描述(由申请者提供)：我们申请的目标是获得一台海德堡光谱OCT仪器，用于哥伦比亚大学哈克内斯眼科研究所的研究。这里的许多教职员工正在进行视网膜退行性疾病的研究，他们依靠最新的成像能力、图像分析和临床分期来与基因分析相关联。此应用程序上指定的用户都是Head项目，这些项目使许多患有老年性黄斑变性(AMD)、Stargardt病、视网膜色素变性和青光眼等眼病的患者受益。他们的工作将有助于我们了解这些疾病，并改善患有这些疾病的患者可以获得的治疗选择。Spectraris OCT能够提供更快、更高分辨率的视网膜层多模式可视化，这有助于所有这些项目，同时改善眼科研究所患者护理的日常管理。Spectraris系统的另一个优点是有一个专用的第二眼睛跟踪设备，它确保眼睛运动的补偿，从而确保采集的图像与光谱域光学相干层析成像(SD-OCT)扫描精确配准。例如，自发荧光异常的位置可以精确地与SD-OCT上看到的结构变化相关联。这种能力对于视网膜疾病的多模式研究至关重要。这也使后续检查能够在完全相同的位置进行扫描，以可靠地测量疾病进展。这在目前使用的单独的成像设备中是不可能的。史密斯博士将与生物医学工程部一起使用这项改进的技术，以改进他们现有的图像分析软件，该软件可以量化彩色眼底、红外和自发荧光图像中的玻璃体和地理萎缩。阿利克梅茨博士正在研究AMD的遗传学，他可以使用该仪器将他的基因发现与疾病的临床阶段联系起来。斯帕罗博士对Stargardt病的研究，曾博士对视网膜色素变性的研究，以及胡德博士对青光眼的研究，都将被用于类似的用途。眼科研究所已经有能力维护和运行该仪器，拥有完全有能力使用光谱仪器的工作人员，并承诺在哥伦比亚大学正在进行的所有研究项目中公平分配它的使用。 公共卫生相关性：由于老年性黄斑变性(AMD)是美国导致失明的主要原因，因此，提高对该疾病的认识所带来的治疗选择和预防护理的改进将对公众健康产生重大影响。哥伦比亚大学哈克内斯眼科研究所对AMD和其他眼病进行的研究将极大地受益于Spectralis的技术，这是一种新的成像仪器，具有更快的图像获取速度和更好的视网膜可视化。

DESCRIPTION (provided by applicant): The goal of our application is to obtain a Heidelberg Spectralis OCT instrument for research at Columbia University's Harkness Eye Institute. The many faculty members here who are conducting research on retinal degenerative disorders rely on the latest imaging capabilities, image analysis and clinical staging to correlate with genetic analyses. The users specified on this application have all headed projects that have benefited many individuals suffering from eye diseases such as age-related macular degeneration (AMD), Stargardt disease, retinitis pigmentosa and glaucoma. Their work will aid in our understanding of these diseases and improve the treatment options that are available to patients living with these conditions. The ability of the Spectralis OCT to provide faster, higher resolution, multimodal visualization of the retinal layers can assist all of these projects while providing daily improvement in the management of patient care at the Eye Institute. Another advantage of the Spectralis system is that there is a dedicated, second eye tracking device which ensures compensation for eye movement and thus that the acquired images are exactly in register with the spectral domain optical coherence tomography (SD-OCT) scans. For example, the location of autofluorescence abnormalities can be precisely correlated with structural changes seen on SD-OCT. This capability is critical for multimodal study of retinal disease. This also enables follow-up examinations to be scanned in exactly the same location for reliable measurement of disease progression. This is not possible with the separate imaging modalities currently in use. The improved technology will be used by Dr. Smith in conjunction with the Department of Biomedical Engineering to improve their existing image analysis software, which quantifies drusen and geographic atrophy in color fundus, infrared, and autofluorescence images. Dr. Allikmets, who is examining the genetics of AMD, can use the instrument to correlate his genetic findings with the clinical stage of the disease. Similar uses will be made in Dr. Sparrow's research on Stargardt disease, Dr. Tsang's research on retinitis pigmentosa and Dr. Hood's work on glaucoma. The Eye Institute already has the capability of maintaining and running the instrument, with staff that are fully capable of using the Spectralis, and a commitment to allocate its usage fairly among all the research projects being conducted at Columbia. Public Health Relevance: Since age-related macular degeneration (AMD) is the leading cause of blindness in the United States, improvement in treatment options and preventive care resulting from improved understanding of the disease would have a large impact on public health. Research done at the Columbia University Harkness Eye Institute on AMD, as well as other eye diseases, would greatly benefit from the technology of the Spectralis, a new imaging instrument with faster image acquisition and improved retinal visualization.